Evidence map›Paper›PMID 37082107›Full record

ArticleImmunotherapy advances2023

Combination CD200R/PD-1 blockade in a humanised mouse model.

Martin Fellermeyer, Consuelo Anzilotti, Christopher Paluch, Richard J Cornall, Simon J Davis, Uzi Gileadi

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Immunotherapy advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Martin FellermeyerMRC Human Immunology Unit, John Radcliffe Hospital, University of Oxford, Oxford, UK.ORCID https://orcid.org/0000-0002-1823-736X
Consuelo AnzilottiMRC Human Immunology Unit, John Radcliffe Hospital, University of Oxford, Oxford, UK.
Christopher PaluchMRC Human Immunology Unit, John Radcliffe Hospital, University of Oxford, Oxford, UK.ORCID https://orcid.org/0000-0002-9087-1920
Richard J CornallMRC Human Immunology Unit, John Radcliffe Hospital, University of Oxford, Oxford, UK.
Simon J DavisMRC Human Immunology Unit, John Radcliffe Hospital, University of Oxford, Oxford, UK.
Uzi GileadiMRC Human Immunology Unit, John Radcliffe Hospital, University of Oxford, Oxford, UK.
Centre for Human Genetics · GBJohn Radcliffe Hospital · GB

Funding

Medical Research Council MC_UU_12010/4Wellcome Trust 207547/Z/17/Z
6 · The paper itself

Abstract

There is an increasing number of immune-checkpoint inhibitors being developed and approved for cancer immunotherapy. Most of the new therapies aim to reactivate tumour-infiltrating T cells, which are responsible for tumour killing. However, in many tumours, the most abundant infiltrating immune cells are macrophages and myeloid cells, which can be tumour-promoting as well as tumouricidal. CD200R was initially identified as a myeloid-restricted, inhibitory immune receptor, but was subsequently also found to be expressed within the lymphoid lineage. Using a mouse model humanised for CD200R and PD-1, we investigated the potential of a combination therapy comprising nivolumab, a clinically approved PD-1 blocking antibody, and OX108, a CD200R antagonist. We produced nivolumab as a murine IgG1 antibody and validated its binding activity

Indexed as

cancer immunotherapyCD200Rmonoclonal antibodynivolumabPD-1

Identifiers

PMID37082107
PMCPMC10112683
OpenAlexW4361245050

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.